Author:
Faggioli Paola,Tamburello Antonio,Roncoroni Lucia,Mazzone Antonino
Abstract
The Schnitzler syndrome (SCS) is a rare, late-onset acquired autoinflammatory syndrome often underdiagnosed. The diagnosis is based on the Lipsker and recently on validated Strasbourg diagnostic criteria (chronic urticarial rash, monoclonal gammopathy, intermittent fever, arthritis, arthralgia, bone involvement, hepatomegaly, splenomegaly, lymphadenopathy, dermal infiltration of neutrophils and laboratory markers of inflammation). Conventional therapies including anti-histamines, anti-inflammatory drugs, corticosteroids and immunosuppressive drugs that are usually ineffective. Recently the gold standard therapy of SCS are considered IL-1 blocking agents as anakinra, canakinumab, rilonacept that led to a significant control of clinical symptoms, even if a relapse could appear at suspension of the treatment. We report a case of a 63-year-old man with a recent diagnosis of SCS - after 6 years of symptoms of disease - refractory to several conventional immunosuppressive therapies and treated with anakinra, with sustained remission of clinic manifestations during treatment at 24 months of follow up.
Reference19 articles.
1. Lésions urticariennes chroniques permanentes (erythème pétaloide?) Cas Clinique;Schnitzler;J Dermatol Angers,1972
2. The Schnitzler syndrome.;Lipsker;Four new cases and review of litherature. Medicine,2001
3. Schnitzler’s syndrome: diagnosis, treatment, and follow up;Simon;Allergy,2013
4. Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients;Gusdorf;Allergy,2017
5. Clinical characterization and longterm follow-up of Schnitzler syndrome;Gameiro;Clin Exp Dermatol,2016
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献